Industries > Pharma > Antisense & RNAi Therapeutics Market Forecast 2020-2030
Back to Pharma Reports
Anti-nuclear Antibody (ANA) Market Forecast 2020-2030

Antisense & RNAi Therapeutics Market Forecast 2020-2030

Antisense & RNAi Therapeutics Market Forecast 2020-2030: Forecasts and Analysis by Type (RNA Interference, Sirna, Mirna and Antisense RNA), by Application (Oncology, Cardiovascular, Renal, Neurodegenerative, Respiratory, Genetic and Infectious Diseases) and Geography with Profiles of Leading Companies

PAGES: 401
PRODUCT CODE: PHA0557
SUBMARKET: Therapeutic Drugs

DOWNLOAD FREE SAMPLE
WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0557 Categories: , Tags: , , ,

According to the report published by Visiongain, the Antisense & RNAi Therapeutics market is projected at USD 1.32 billion in 2020 and is anticipated to see a CAGR of 7.5 percent in the 2020-2030 prediction. Antisense technology offers the chance to control the function of the gene and this is regarded as an efficient therapy for different illnesses. The businesses cash on this chance and invest in R&D in this industry.

During disease progression, cellular RNAs perform key functions and constitute a varied and mainly untapped category of biomolecules that can be used to develop drugs.RNA organisms include template RNAs (mRNAs) which are transformed into dna, lengthy non-coding RNAs including RNAs (tRNAs) and ribosomal RNAs (rRNAs), and tiny non-coding RNAs such as nano RNAs (miRNAs) and tiny RNAs (siRNAs).

Using RNA species as medicinal agents provides drug designers with fresh possibilities and the opportunity to build antibodies against’ undruggable’ genes and gene products. In addition, fresh testing instruments now facilitate targeting structures of disease-associated RNA.

However, the development of RNA-based therapeutics is not without its difficulties as RNA is inherently unstable and susceptible to degradation by effective and continuous ribonucleases (RNases), is possibly immunogenic and may involve an effective and precise travel car to reach cells and across the lipid bilayer. These growth obstacles were mainly resolved by chemically changing RNA to improve its strength and by using RNA medication distribution artificial agents such as lipid nanoparticles (LNP) or polymer-based nanoparticles (PNP) devices.

Antisense RNA
Most present antisense RNAs have been created from complementary sequences to target mRNA and are brought into cells to decrease or alter protein expression when attached to mRNA to relieve disease signs. Sequence-specific antisense RNAs prevent gene expression by modifying mRNA splicing, stopping synthesis of mRNA and causing ribonuclease (RNase H) degradation of mRNA.

Nevertheless, their intrinsic toxicity resulted to the growth of altered antisense RNAs that are either more nuclease susceptible but still activate RNase H or attach to RNA without activating RNase H. Modified antisense RNAs show significantly improved half-life tissue and continuous inhibitory action.

Why you should buy Antisense & RNAi Therapeutics Market Forecast 2020-2030:
 Forecasts and Analysis by
and Geography, with Profiles of Leading Companies
What is the future of the Antisense & RNAi Therapeutics market? Visiongain’s comprehensive analysis contains highly quantitative content delivering solid conclusions benefiting your analysis and illustrates new opportunities and potential revenue streams helping you to remain competitive. This definitive report will benefit your decision making and help to direct your future business strategy.
We guarantee in this 171 page report you will receive the following key information –

– View Antisense & RNAi Therapeutics market forecasts and analysis from 2020-2030 to keep you ahead of your competitors and ensure you exploit key business opportunities
– The report provides detailed sales projections of the market, the competitors, and the commercial drivers and restraints allowing you to more effectively compete in the market. In addition to market forecasts from 2020-2030, our new study shows current market data, original critical analysis, and revealing insight into commercial developments
– Antisense & RNAi Therapeutics revenue forecast
– Antisense & RNAi Therapeutics connections forecast
Emerging RNA technologies
New techniques and methods for targeting RNA include the implementation of CRISPR-Cas9 genome processing technology, DNA-driven RNA intrusion (ddRNAi) technology and the creation of RNA or RNA-modifying enzyme specific small molecule modulators (14). For instance, CAL-1, the principal therapeutic applicant for Calimmune, reflects an RNA-based gene therapy that uses ddRNAi to suppress the CCR5 gene to regulate HIV infection and prevent people with HIV from creating AIDS.

In latest years, several firms have been created that concentrate on the growth of small-molecule RNA modulators. Expansion Therapeutics Inc (San Diego, California, USA), for instance, has created a tool to detect tiny molecules that interact with RNA (SMiRNA) across multiple therapy fields, including mRNA and various non-coding RNAs. Furthermore, STORM Therapeutics (Cambridge, UK) specializes in RNA epigenetics and the production of RNA-modifying enzyme small-molecule agents for cancer treatment. Targeting introns (non-coding areas of an RNA transcript or DNA sequence within a genome) or exons (coding areas) splice-variant regulate structures.

Skyhawk Therapeutics Inc. (Waltham, Massachusetts, USA), for instance, was established this year with a tool to define RNA spliceosome complicated specific small molecule modulators targeting RNA mis-splicing (exon stopping), driving various illnesses including neurological conditions and cancer. These emerging technologies give excellent possibilities for developing additional approaches for drug development targeting RNA.

To present, four RNA-based medications–Macugen, Exondys 51, Spinraza and Onpattro–have produced it to retail effectively and several other RNA officers are presently undergoing clinical programs. Additionally, fresh testing instruments make it simpler to recognize targeting patterns of disease-associated RNA. To date, attempts to discover drugs have concentrated mainly on mRNAs, silencing gene expression using antisense RNAs and siRNAs, or creating aptamers of RNA that connect to particular molecular objectives. Emerging techniques and modalities, including genome processing for CRISPR-Cas9 and RNA-modifying enzyme modulators for small molecules, give additional possibilities for drug discovery targeting for mRNA. Future advances in RNA therapeutic design and delivery technologies will help exploit the full commercial potential of RNA-based therapeutics.

– Examine 122 tables, charts, and graphs.
– Let our analysts present you with a thorough assessment of the current and future Antisense & RNAi Therapeutics market prospects.
– This analysis will achieve quicker, easier understanding. Also you will gain from our analyst’s industry expertise allowing you to demonstrate your authority on the Antisense & RNAi Therapeutics sector

– Discover sales predictions for the key end use submarkets from 2020-2030
– What are the dynamics of the Antisense & RNAi Therapeutics industry? Which submarkets will generate the most revenue? Use our forecasts and expert insight to grow your business and give you more industry influence. Find where you can gain and how your organisation can succeed. Avoid falling behind. Stay informed about the potential for each of these Antisense & RNAi Therapeutics submarkets with individual forecasts and analysis from 2020-2030.
– Application submarket forecast 2020-2030
– Administration submarket forecast 2020-2030
– Technology submarket forecast 2020-2030

– Learn about the market prospects for the leading Antisense & RNAi Therapeutics market segments 2020-2030
– How will various value chain members perform over the forecast period? Discover where the highest revenue potential lies from 2020-2030, learning about how Antisense & RNAi Therapeutics revenue trickles down through the various market segments. These forecasts will also reveal the competitive landscape. You will see what is happening, explaining the challenges, trends, competitors, and market opportunities. Our report reveals forecasts for the 3 leading segmentations as follows.

– Application Revenue Forecast 2020-2030
– Infectious Diseases Market Forecast, 2020-2030
– Genetic Disorders Market Forecast, 2020-2030
– Neurodegenerative Disorders Market Forecast, 2020-2030
– Renal Diseases Market Forecast, 2020-2030
– Oncology Market Forecast, 2020-2030
– Oncology Market Forecast, 2020-2030
– Cardiovascular Diseases (CVDs) Market Forecast, 2020-2030
– Respiratory Disorders Market Forecast, 2020-2030
– Other Application Market Forecast, 2020-2030

– Administration Revenue Forecast 2020-2030
– Pulmonary Delivery Market Forecast, 2020-2030
– Intravenous Injections Market Forecast, 2020-2030
– Intra-dermal Injections Market Forecast, 2020-2030
– Intraperitoneal Injections Market Forecast, 2020-2030
– Topical Delivery Market Forecast, 2020-2030
– Other Administration Market Forecast, 2020-2030

– Technology Revenue Forecast 2020-2030
– siRNA Market Forecast, 2020-2030
– miRNA Market Forecast, 2020-2030
– Antisense RNA Market Forecast, 2020-2030
– Other Technology Market Forecast, 2020-2030

– Understand the prospects for the 4 regional and the leading 12 national Antisense & RNAi Therapeutics markets – where will the highest revenues and opportunities occur?
– Learn about the market potential for Antisense & RNAi Therapeutics companies in the developed and developing countries, from 2019 onwards. You will see where and how opportunities exist with revealing individual market forecasts and analysis from 2020-2030 for 12 leading national markets by revenue, as well as segmented regional forecasts

– North America Antisense & RNAi Therapeutics revenue forecast 2020-2030
– US Antisense & RNAi Therapeutics revenue forecast 2020-2030
– Canada Antisense & RNAi Therapeutics revenue forecast 2020-2030
– Mexico Antisense & RNAi Therapeutics revenue forecast 2020-2030

– North America Antisense & RNAi Therapeutics by Application revenue forecast 2020-2030
– North America Antisense & RNAi Therapeutics by Administration revenue forecast 2020-2030
– North America Antisense & RNAi Therapeutics by Technology revenue forecast 2020-2030
– Asia Pacific Antisense & RNAi Therapeutics revenue forecast 2020-2030
– China Antisense & RNAi Therapeutics revenue forecast 2020-2030
– Japan Antisense & RNAi Therapeutics revenue forecast 2020-2030
– India Antisense & RNAi Therapeutics revenue forecast 2020-2030
– Australia Antisense & RNAi Therapeutics revenue forecast 2020-2030
– Rest of Asia Pacific Antisense & RNAi Therapeutics revenue forecast 2020-2030
– Asia Pacific Antisense & RNAi Therapeutics by Application revenue forecast 2020-2030
– Asia Pacific Antisense & RNAi Therapeutics by Administration revenue forecast 2020-2030
– Asia Pacific Antisense & RNAi Therapeutics by Technology revenue forecast 2020-2030
– European Antisense & RNAi Therapeutics revenue forecast 2020-2030
– Germany Antisense & RNAi Therapeutics revenue forecast 2020-2030
– UK Antisense & RNAi Therapeutics revenue forecast 2020-2030
– France Antisense & RNAi Therapeutics revenue forecast 2020-2030
– Italy Antisense & RNAi Therapeutics revenue forecast 2020-2030
– Spain Antisense & RNAi Therapeutics revenue forecast 2020-2030
– Rest of Europe Antisense & RNAi Therapeutics revenue forecast 2020-2030
– European Antisense & RNAi Therapeutics by Application revenue forecast 2020-2030
– European Antisense & RNAi Therapeutics by Administration revenue forecast 2020-2030
– European Antisense & RNAi Therapeutics by Technology revenue forecast 2020-2030
– Rest of World Antisense & RNAi Therapeutics revenue forecast 2020-2030
– Rest of World Antisense & RNAi Therapeutics by Application revenue forecast 2020-2030
– Rest of World Antisense & RNAi Therapeutics by Administration revenue forecast 2020-2030
– Rest of World Antisense & RNAi Therapeutics by Technology revenue forecast 2020-2030
• Explore the factors affecting Antisense & RNAi Therapeutics product developers, and everyone within the value chain. Learn about the forces influencing market dynamics.
– Discover what the present and future outlook for business will be. Learn about the following business critical issues
– Research and development (R&D) strategy
– Technological issues and constraints.
– Competition from new product types
– Increasing specialisation by leading players
– Increasing industry consolidation.
– Advances in product quality
– Analysis of barriers to entry

– Identify who the leading companies are in the Antisense & RNAi Therapeutics industry
– Our report reveals the technologies and companies which hold the greatest potential. In particular, exploring and analyzing the activities of these companies: See where the expected gains will be. View visiongain’s assessment of the prospects for established competitors, rising companies, and new market entrants. Our work explains that potential, helping you stay ahead. Gain a thorough understanding of the competitive landscape with profiles of 10 leading Antisense & RNAi Therapeutics companies examining their positioning, capabilities, product portfolios, R&D activity, services, focus, strategies, M&A activity, and future outlook.

Leading Companies in the Global Antisense & RNAi Therapeutics Market
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
Benitec Biopharma Ltd.
Acuitas Therapeutics
Olix Pharmaceuticals
GlaxoSmithKline Plc
Sanofi S.A
Arbutus Biopharma
Silence Therapeutics Plc
Enzon Pharmaceuticals Inc

Discover Information found nowhere else in this independent assessment of the Antisense & RNAi Therapeutics market
The Antisense & RNAi Therapeutics Market Forecast 2020-2030: Forecasts and Analysis By Application, By Administration, By Technology and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Antisense & RNAi Therapeutics sector analysis. With the independent business intelligence found only in our work, you will discover where the prospects are for profit. In particular, our new research provides you with key strategic advantages: Our informed forecasts, independent and objective analysis, exclusive interviews and revealing company profiles will provide you with that necessary edge, allowing you to gain ground over your competitors.

With this report you are less likely to fall behind in knowledge or miss crucial business opportunities. You will save time and receive recognition for your market insight. See how you this report could benefit and enhance your research, analysis, company presentations and ultimately your individual business decisions and your company’s prospects.

What makes this report unique?
Visiongain’s research methodology involves an exclusive blend of primary and secondary sources providing informed analysis. This methodology allows insight into the key drivers and restraints behind market dynamics and competitive developments. The report therefore presents an ideal balance of qualitative analysis combined with extensive quantitative data including global, submarket and regional markets forecasts from 2020-2030

How the Antisense & RNAi Therapeutics Market Forecast 2020-2030: Forecasts and Analysis By Application, By Administration, By Technology and and Geography, with Profiles of Leading Companies report can benefit you
Visiongain’s report is for anyone requiring analysis of the Antisense & RNAi Therapeutics market. You will discover market forecasts, technological trends, predictions and expert opinion providing you with independent analysis derived from our extensive primary and secondary research. Only by purchasing this report will you receive this critical business intelligence revealing where revenue growth is likely and where the lucrative potential market prospects are. Don’t miss this key opportunity to gain a competitive advantage.

Avoid falling behind your competitors, overlooking critical business opportunities or losing industry influence. In our new report you will discover forecasts from 2020-2030 at the global, submarket, and national level. The report also assesses technologies, competitive forces and expected product pipeline developments. Read on to discover the prospects for the Antisense & RNAi Therapeutics sector and find out what its future market prospects are.

If you buy our report today your knowledge will stay one step ahead of your competitors. Discover how our report could benefit your research, analyses and strategic decisions, saving you time. To gain an understanding of how to tap into the potential of this market and stay one step ahead of the competition you must order now our report the Antisense & RNAi Therapeutics Market Forecast 2020-2030: Forecasts and Analysis By Application, By Administration, By Technology and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Antisense & RNAi Therapeutics sector analysis. Avoid missing out – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Antisense & RNAi Therapeutics Market Forecast 2020-2030

    Related reports

    Download sample pages

    Complete the form below to download your free sample pages for Antisense & RNAi Therapeutics Market Forecast 2020-2030

      Connect with us

      Visiongain Pharma

      Visiongain Pharma

      Visiongain Pharma

      Latest Pharma news

      Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

      The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

      23 April 2024

      READ
      Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

      The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

      18 April 2024

      READ
      Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

      The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

      17 April 2024

      READ
      Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

      The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

      12 April 2024

      READ